• Life sciences M&A update: H2-2017

    Baker Tilly Capital, LLC's Life sciences M&A newsletter provides an overview of the current industry's marketplace, highlighting key trends impacting performance and U.S. M&A activity.
  • Healthcare M&A update: Q4-2017

    There were 264 reported healthcare M&A transactions that closed during the fourth quarter of 2017, with an aggregate reported deal value of $68.8 billion. Of these transactions, 46 were middle-market transactions with a reported deal value of $8.7 billion.
  • Healthcare M&A update: Q3-2017

    There were 284 reported M&A transactions that closed during the third quarter of 2017 (Q3-2017), up from 277 transactions during the previous quarter. Reported closed transactions in Q3-2017 decreased 27.4 percent compared to 391 closed deals for the same period in 2016.
  • M&A spotlight: Behavioral health

    The behavioral health industry has seen growing consolidation as strategic and financial buyers seek to capitalize on significant industry fragmentation and demand that currently outstrips supply.
  • Life sciences M&A update: H1-2017

    Baker Tilly Capital, LLC's life sciences M&A newsletter provides an overview of the U.S. medical devices and products, pharmaceutical (pharma) and pharma outsourced services sectors, including recent performance and M&A trends.